Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3582MR)

This product GTTS-WQ3582MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3582MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6301MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ12338MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ4483MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ11175MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ8492MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ7356MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ13086MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ14156MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aIL6R88
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW